Odyssey Therapeutics, Inc.
ODTX
$19.27
$0.381.99%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Net Income | 0.45% | ||||
| Total Depreciation and Amortization | -9.85% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | -14.56% | ||||
| Change in Net Operating Assets | -36.07% | ||||
| Cash from Operations | -6.25% | ||||
| Capital Expenditure | 84.03% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -0.14% | ||||
| Cash from Investing | 1.98% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | 31.43% | ||||
| Issuance of Common Stock | 177.02% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -- | ||||
| Cash from Financing | 142.00% | ||||
| Foreign Exchange rate Adjustments | -65.22% | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -35.50% | ||||